Overcoming Animal Testing with Advanced Cell Models

by Sartorius Stedim Spain

“How do we break the walls of realizing the full potential of organoids and microtissues as an alternative to animal testing?” In line with the motto of the Falling Walls Science Summit 2024 in Be...

Read more

Un nuevo enfoque con células de memoria abre posibilidades en la lucha contra infecciones por bacterias farmacorresistentes

by Instituto de Biomedicina de Sevilla - IBIS

Una investigación del Instituto de Biomedicina de Sevilla (IBiS) desarrolla un enfoque innovador basado en la transferencia adoptiva de células de memoria para combatir infecciones por Acinetobacter...

Read more

Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial

by Ysios Capital

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages over current therapies

Read more

Avances de 2024 en el diagnóstico y tratamiento del cáncer de pulmón desde la perspectiva de la medicina de precisión

by Revista Genética Médica

El cáncer de pulmón representa una de las principales causas de mortalidad por cáncer a nivel mundial. Cada año se diagnostican 2.2 millones de nuevos casos, cuyo pronóstico depende de cómo de t...

Read more

La EMA recomienda ahora aprobar el polémico fármaco lecanemab contra el alzhéimer

by Agencia Sinc

La Agencia Europea del Medicamento ha cambiado de opinión y respalda la utilización de este medicamento para el tratamiento del alzhéimer en fases iniciales. Aunque reduce un 27 % el deterioro cogn...

Read more

Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH...

Read more

Biorce closes €3.5m round led by YZR Capital and Mustard Seed

by Biorce

Biorce, a Barcelona based TechBio company dedicated to transforming clinical trials through artificial intelligence, has announced the successful completion of a €3.5 million funding round. The inve...

Read more

Gate2Brain Receives EMA Orphan Drug Designation for Its Pediatric Cancer Treatment

by IRB Barcelona - Instituto de Investigación Biomédica

The IRB Barcelona spin-off Gate2Brain has reached a major milestone in the fight against pediatric brain tumors by obtaining Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for ...

Read more

El papel del ADN circular extracromosómico en la progresión del cáncer es mayor de lo esperado

by Revista Genética Médica

Nuevas evidencias amplían el papel del ADN extracromosómico en el cáncer y ofrecen una aproximación terapeútica.

Read more

The Screening Platform at IRB Barcelona: Key to Advancing Personalized Medicine

by IRB Barcelona - Instituto de Investigación Biomédica

The Drug Screening Platform at IRB Barcelona was launched 3 years ago to support the scientific community in the early stages of drug development.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream